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Interleukin-17-producing cd+ T cells protect NOD mice from type 1
diabetes through a mechanism involving transforming growth
factor-b
Introduction
The non-obese diabetic (NOD) mouse spontaneously
develops autoimmune diabetes and represents a good
model for human type 1 diabetes.1 The pathogenic roles
of T helper type 1 (Th1) cells in autoimmune diabetes
have been well defined. Th1 cell cytokines, such as inter-
leukin (IL)-12 and interferon (IFN)-c, have been impli-
cated in promoting diabetogenesis, although there have
been recent reports that IFN-c is non-pathogenic in the
later phase of diabetes.2 Therapies designed to balance the
Th1/Th2 response in NOD mice have been tested and
found to work well in preventing diabetes in this model,
which finally defined the pathogenic roles of Th1 cells in
type 1 diabetes in these mice.3,4 However, the aetiology of
autoimmune diabetes is complex and the mechanisms
involved need to be explored to find more effective
intervention strategies.
Recently, a new CD4+ T-cell lineage, the Th17 cell
lineage, was identified and has been found to be involved
in many autoimmune and hypersensitivity diseases, such
as multiple sclerosis, rheumatoid arthritis and asthma.5–8
IL-17 knockout or neutralization significantly delays or
prevents the disease process in collagen-induced
arthritis and experimental autoimmune encephalomyelitis
(EAE).6,7 However, the pathogenesis of the prevalent
autoimmune disease, type 1 diabetes, and the role of
Th17 cells in it remain largely unclear. Recently, using
polarized Th17 and Th1 cells from NOD.BDC transgenic
mice as cell models, some groups reported that Th17 cells
play a less important role in the pathogenesis of diabetes
than Th1 cells.9,10 However, under natural conditions, the
production and role of IL-17 in the progress of diabetes
in NOD mice remain largely unclear.
In addition to Th17 cells, cd T-cell receptor (TCR)-bear-
ing cells (cd T cells) are an important source of IL-17.11,12
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Summary
Whether interleukin (IL)-17 promotes a diabetogenic response remains
unclear. Here we examined the effects of neutralization of IL-17 on the
progress of adoptively transferred diabetes. IL-17-producing cells in
non-obese diabetic (NOD) mice were identified and their role in the
pathogenesis of diabetes examined using transfer and co-transfer assays.
Unexpectedly, we found that in vivo neutralization of IL-17 did not
protect NOD–severe combined immunodeficiency (SCID) mice against
diabetes transferred by diabetic splenocytes. In NOD mice, cd+ T cells
were dominated by IL-17-producing cells and were found to be the major
source of IL-17. Interestingly, these IL-17-producing cd T cells did not
exacerbate diabetes in an adoptive transfer model, but had a regulatory
effect, protecting NOD mice from diabetes by up-regulating transforming
growth factor (TGF)-b production. Our data suggest that the presence of
IL-17 did not increase the chance of the development of diabetes; cd
T cells protected NOD mice from diabetes in a TGF-b-dependent manner,
irrespective of their role as major IL-17 producers.
Keywords: autoimmune diabetes; interleukin-17; non-obese diabetic
(NOD); transforming growth factor-b; cd T cells
Abbreviation: NOD, non-obese diabetic.
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I M M U N O L O G Y O R I G I N A L A R T I C L E
In contrast to conventional T cells, cd T cells constitute
only a small proportion (1–5%) of the lymphocytes that
circulate in the blood and peripheral organs. The use of
mice genetically engineered to be deficient in cd T cells in
experimental models of infectious and autoimmune dis-
eases, including autoimmune diabetes, has focused atten-
tion on the immunoregulatory role of these cells.13–19
However, the mechanisms used by cd T cells and the iden-
tity and molecular nature of the cells with which they
interact have not been fully determined.20 As cd T cells
have recently been shown to express high levels of IL-17,11
it is of interest to evaluate the relationship between IL-17-
producing cd T cells and autoimmune diseases.
To investigate the roles of Th17 cells and the IL-17 they
produce in the pathogenesis of autoimmune diabetes, we
first measured IL-17 production in diabetic and non-
diabetic NOD mice. We then performed in vivo IL-17
neutralization to evaluate the effects on the pathogenesis
of diabetes. The kinetics of IL-17 and IFN-c production
during the disease process in NOD mice were also fol-
lowed and compared. Importantly, we found that cd T
cells from NOD mice were dominated by IL-17+ T cells,
and therefore studied the roles of IL-17-producing cd T




Diabetes-prone NOD mice and immunodeficient NOD-
SCID mice (used for all transfer experiments except one in
which cd T cells were transferred into NOD mice to exam-
ine their possible regulatory effect) were originally
obtained from the Jackson Laboratory (Jersey, NJ), and
then bred in our facilities under specific pathogen-free
conditions. The care, use and treatment of mice in this
study were in strict agreement with the guidelines for the
care and use of laboratory animals of the Institute of Basic
Medical Sciences. In our institute, the incidence of sponta-
neous diabetes in NOD mice is 80–90% at 30 weeks of age.
Blood glucose levels were measured biweekly or every other
day (for NOD-SCID recipients) and the mice were consid-
ered to have type 1 diabetes when glucose levels exceeded
113 mM, as, in our facilities, spontaneous decreases after
this level has been reached are rarely observed.
Isolation of cd T cells
cd T cells were isolated from splenocytes using Micro-
beads (Miltenyi Biotec Inc., Bergish Gladbach, Germany)
according to the manufacturer’s protocol. Seven- to
eight-week-old non-diabetic female NOD mice were used
as the source of cd T cells. Briefly, splenocytes were col-
lected and lymphocytes prepared by Ficoll centrifugation
and washed twice with phosphate-buffered saline (PBS),
pH 72, containing 05% bovine serum albumin (BSA)
and 2 mM ethylenediaminetetraacetic acid (EDTA) (PBS-
BSA-EDTA). An aliquot containing 107 cells was then
spun down and the cells re-suspended in 50 ll of PBS-
BSA-EDTA, and then 5 ll of phycoerythrin (PE)-conju-
gated anti-cd antibody (GL3; eBiosciences, San Diego,
CA) was added and the mixture was incubated at 4 for
15 min. After two PBS-BSA-EDTA washes, the cells were
re-suspended in 40 ll of PBS-BSA-EDTA and 10 ll of
anti-PE Microbeads (Miltenyi Biotec Inc.) was added and
the mixture was incubated at 4 for 15 min. Finally, after
two PBS-BSA-EDTA washes, the cells were applied to
MACS Separator columns (Miltenyi Biotec Inc.) and sep-
arated into bound and non-bound fractions. The bound
fraction was eluted and the purity of the isolated cell frac-
tion determined by flow cytometry analysis (95% pure cd
T cells). Data collection and analysis were performed by
FACScaliber flow cytometry (BD Biosciences, San Jose,
CA) using CELLQUEST software (BD Biosciences).
Enzyme-linked immunosorbent assay (ELISA)
measurement of cytokine production
Cytokine secretion by splenocytes or pancreatic draining
lymph node cells was determined by ELISA as recom-
mended by the kit manufacturer (eBioscience). Briefly,
cells from female NOD mice (5 · 105) were incubated in
96-well flat-bottomed microtitre plates with 01 lg/ml of
anti-CD3 antibody (1452C11) in the presence or absence
of 10 ng/ml of recombinant mouse IL-23 (eBioscience)
and the supernatants were harvested after 48 hr. Levels of
IL-17, IFN-c, TGF-b and IL-10 were determined in tripli-
cate in 01 ml of supernatant using a sandwich ELISA
method. For TGF-b analysis, samples were first activated
with acid (1N HCL), followed by neutralization with 1N
NaOH as described in the manufacturer’s protocol to
determine active TGF-b levels.
Adoptive transfer experiments
For disease transfer using splenocytes from diabetic NOD
mice (‘diabetic splenocytes’) and for the IL-17 neutraliza-
tion experiment, 5 · 106 diabetic splenocytes were
injected intravenously (i.v.) into female NOD-SCID mice
(4 to 6 weeks old). Anti-IL-17 antibody (5010411; R&D
Systems, Minneapolis, MN; 200 lg/mouse) was injected
i.v. on the day of transfer, and two additional i.v. injec-
tions were given on days 4 and 16 after transfer.21 Mice
receiving diabetic splenocytes plus immunoglobulin G
(IgG) isotype antibody or splenocytes from 6- to 8-week-
old non-diabetic mice (‘naı̈ve splenocytes’) were used as
controls.
To examine whether cd T cells protected against the
transfer of diabetes, (i) 15 · 106 purified cd T cells from
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8-week-old non-diabetic NOD mice were injected i.v. into
7-week-old female NOD mice or (ii) purified cd T cells
from 8-week-old non-diabetic NOD mice were co-trans-
ferred with diabetic splenocytes at different ratios into
female NOD-SCID mice (4 to 6 weeks old).
Blood glucose levels were then monitored.
Administration of anti-TGF-b antibody
Splenocytes from 15-week-old diabetic NOD mice
(5 · 106) and cd T cells from 8-week-old non-diabetic
NOD mice (15 · 106) were co-transferred into NOD-
SCID mice. One group of recipients was injected i.v. with
05 mg of anti-TGF-b antibody (1D11; mouse IgG1; R&D
Systems) every 4–5 days and the other group received the
same amount of control mouse IgG.22 NOD-SCID recipi-
ents receiving 5 · 106 diabetic splenocytes were used as
positive controls.
Flow cytometry
For staining for CD4, CD8 or cd TCR, splenocytes or
cells from the pancreatic draining lymph nodes were
incubated for 30 min at 4 with PE-conjugated anti-CD4
or anti-CD8 antibodies or fluorescein isothiocyanate
(FITC)-conjugated anti-cd TCR antibodies (all from Bio-
legend, San Diego, USA), and then washed and analysed.
For intracellular IL-17 staining, cells were stimulated
in vitro for 4 hr with 50 ng/ml of phorbol 12-myristate
13-acetate (PMA), 1 lg/ml of ionomycin, and 1 lg/ml of
brefeldin A (Sigma, St Louis, MO), and then stained with
FITC-conjugated anti-cd TCR antibodies for 30 min at
4. They were then washed, fixed overnight with Fix/Perm
buffer (eBioscience), washed with permeabilization buffer
(eBioscience), and stained with PE-conjugated anti-IL-17
antibodies (clone FJK-16s; eBioscience) and analysed on a
FACScalibur flow cytometer.
Histology
The pancreas was removed from NOD-SCID mice and
fixed in 10% buffered formalin, embedded in paraffin,
sectioned at 45 lm, and stained with haematoxylin and
eosin (H&E). Insulitis grade was determined as follows: 0,
normal islet; 1, mononuclear infiltration, largely in the
periphery, in < 25% of the islet; 2, 25–50% of the islet
showing mononuclear infiltration; 3, > 50% of the islet
showing mononuclear infiltration; and 4, small, com-
pletely destroyed islet with few mononuclear cells.
Statistical analysis
The log-rank test was used for analysis of the incidence of
diabetes in the experimental and control groups. For the
remainder of the experiments, P-values were calculated
with the two-tailed Student’s unpaired t-test. A P-value of
 005 was considered to be statistically significant.
Results
In vivo neutralization of IL-17 does not prevent the
development of adoptively transferred diabetes
To examine the role of IL-17 in the pathogenesis of dia-
betes in diabetes-prone NOD mice, we first compared
IL-17 production in diabetic and non-diabetic NOD mice
at about 15 weeks of age. As serum IL-17 was undetectable
(data not shown), in vitro IL-17 production by lympho-
cytes was measured after 48 hr of stimulation with anti-
mouse CD3 antibody (01 lg/ml). Our data showed that
splenocytes from diabetic mice (‘diabetic splenocytes’)
produced significantly higher levels of IL-17 than those
from non-diabetic age-matched NOD mice (Fig. 1a). To
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Figure 1. In vivo neutralization of interleukin (IL)-17 does not pro-
tect against diabetes transferred by diabetic splenocytes. (a) Spleno-
cytes from 15-week-old female diabetic or age- and sex-matched
non-diabetic non-obese diabetic (NOD) mice were stimulated in vitro
for 2 days with anti-CD3 antibody (01 lg/ml) and IL-23 (10 ng/
ml), and then the supernatants were collected and tested for IL-17
production by enzyme-linked immunosorbent assay (ELISA) (n = 4
per group). Cells cultured with medium alone were used as a nega-
tive control. IL-17 was undetectable in the control well (data not
shown). **P < 001 by Student’s t-test. (b) One group of NOD–
severe combined immunodeficiency (SCID) mice were injected intra-
venously (i.v.) with non-diabetic splenocytes (from 6- to 8-week-old
mice) and left untreated, while two groups were injected with dia-
betic splenocytes (5 · 106 per mouse), and then, on days 0, 4 and
16, with 200 lg of either rat anti-mouse IL-17 antibody (5010411;
R&D Systems) or control rat immunoglobulin (IgG), and blood glu-
cose was measured weekly. Compared with IgG-treated controls,
anti-IL-17 antibody administration did not reduce the incidence of
diabetes in NOD-SCID recipients (P > 005 by log-rank test). The
data shown are representative of those for three independent experi-
ments. In each experiment, 10 mice were used in each group.
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the pathogenesis of autoimmune diabetes, a diabetes cell
transfer study in immunodeficient NOD-SCID mice was
performed in which neutralizing antibody was given
simultaneously to block IL-17 function. We found that
mice co-injected with diabetic splenocytes and anti-IL-17
antibody or isotype control showed a comparable inci-
dence of diabetes with no significant difference in onset
(Fig. 1b), indicating that neutralization of IL-17 did not
prevent transfer of diabetes by diabetic splenocytes. Proof
that the antibody was effective in vivo was obtained by
examining the effect of neutralization on the IL-17-
producing ability of recipient T cells when the mice were
killed at 4 weeks after cell transfer. In response to stimu-
lation with anti-CD3 antibody, T cells from anti-IL-17
antibody-injected NOD-SCID mice showed significantly
decreased IL-17 production compared with isotype con-
trol-injected mice (data not shown). These results show
that antibody administration efficiently blocked IL-17
production, but did not prevent diabetes in NOD mice.
IL-23-expanded diabetic splenocytes produce higher
levels of IL-17 than non-treated cells, but induce
comparable levels of diabetes
To test the role of IL-17 in the pathogenesis of diabetes
in another way, diabetic splenocytes were expanded by
incubation for 24 hr with anti-mouse CD3 antibody with
or without recombinant mouse IL-23 (10 ng/ml). Com-
pared with the non-IL-23-treated cells, the diabetic
splenocytes expanded in the presence of IL-23 expressed
higher levels of IL-17 (Fig. 2a) and comparable levels of
IFN-c (Fig. 2b). When the two different preparations of
diabetic splenocytes were transferred into NOD-SCID
mice, they also induced a comparable incidence of diabe-
tes (Fig. 2c). This again suggests that the presence of
IL-17 did not increase the incidence of diabetes develop-
ment. As IFN-c is a signature cytokine of Th1 cells, which
might be involved in the onset of diabetes, we compared
the kinetics of IL-17 and IFN-c production by splenocytes
in response to stimulation with anti-mouse CD3 antibody
(01 lg/ml) in NOD mice at different ages. We found
that production of IFN-c peaked at 7 weeks of age, the
age of insulitis onset in NOD mice, and then gradually
decreased, while IL-17 production remained at a similar
level or increased slightly with age (Fig. 2d), which, to
some extent, suggests that Th1 cells, and not Th17 cells,
are involved in the pathogenesis of type 1 diabetes in
NOD mice. Similar results were obtained using pancreatic
draining lymph nodes (data not shown).
IL-17 is mainly expressed by CD4– CD8– cd T cells in
NOD mice
Next, to test the potential role of IL-17 in the patho-
genesis of type 1 diabetes in another way, IL-17-producing









































































Figure 2. Interleukin (IL)-23-expanded diabetic splenocytes produced higher levels of IL-17, but induced comparable diabetes in non-obese dia-
betic–severe combined immunodeficiency (NOD-SCID) mice compared with non-treated diabetic splenocytes. (a, b) Diabetic splenocytes were
expanded in vitro for 24 hr using anti-mouse CD3 antibody with or without IL-23, and then the supernatants were collected and analysed for
IL-17 (a) and interferon (IFN)-c (b) production (n = 4 per group). **P < 001 by Student’s t-test. (c) Diabetic splenocytes expanded with anti-
mouse CD3 antibody plus recombinant IL-23 (rIL-23) or medium were transferred into NOD-SCID mice, and blood glucose levels were followed
(n = 10 per group). Compared with the medium-cultured controls, IL-23-expanded diabetic splenocytes did not increase the incidence of diabe-
tes in NOD-SCID recipients (P > 005 by log-rank test). (d) Female mice of different ages were killed and their splenocytes stimulated in vitro
for 48 hr with anti-CD3 antibody, and then the supernatants were tested for IL-17 and IFN-c by enzyme-linked immunosorbent assay (ELISA)
(n = 4 per group). The data are representative of those for two independent assays.
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IL-17 was found to be mainly expressed by cd T cells,
and not CD4+ or CD8+ T cells (Fig. 3a), and this was
more evident when T cells were in vitro expanded with
recombinant mouse IL-23 (Fig. 3b). Finally, purified cd
T cells were tested for IL-17 expression and production
and the results showed that purified cd T cells were
dominated by IL-17-expressing cells (Fig. 3c) and, in
response to IL-23 stimulation, produced 10-fold more
IL-17 than cd TCR-negative splenocytes (Fig. 3d).
IL-17-producing cd T cells protect NOD mice from
the induction of diabetes
As cd T cells produce high levels of IL-17, it was of inter-
est to examine their role in autoimmune diabetes. To
investigate this, we first examined the percentage of cd
T cells in NOD mice and found that the percentage of cd
T cells in the peripheral lymphocytes was higher in non-
diabetic than in age-matched diabetic NOD mice (Fig. 4a),
and this difference was even more marked after the
T cells had been expanded with recombinant IL-23 in vitro
(Fig. 4b). Similar results were obtained with lymphocytes
from the pancreatic draining lymph nodes (data not
shown). This suggested that cd T cells might have a pro-
tective effect in NOD mice. To examine whether there
were differences between cd T cells derived from non-dia-
betic and diabetic NOD mice, IL-17 production by cd
T cells were analysed, but the two populations produced
comparable levels of IL-17 (Fig. 4c). To directly investi-
gate the effects of IL-17-producing cd T cells in NOD
mice, cd T cells from non-diabetic NOD mice were puri-
fied and injected into female 7-week-old NOD mice and
different ratios of purified cd T cells from non-diabetic
NOD mice and diabetic splenocytes were co-transferred
into NOD-SCID mice. Unexpectedly, we found that
IL-17-producing cd T cells did not induce diabetes in NOD
mice, but actually decreased its incidence (P = 00046 by
log-rank test) (Fig. 5a). In addition, the co-transfer study
showed that cd T cells had a marked effect in protecting
NOD-SCID mice from the insulitis and diabetes induced




































Figure 3. Interleukin (IL)-17 expression in non-obese diabetic
(NOD) mice is dominated by CD4) CD8) cd+ T cells. (a, b) Freshly
isolated (a) or IL-23-expanded (b) splenocytes from female NOD
mice were double-stained with fluorescein isothiocyanate (FITC)-
conjugated antibodies against CD4, CD8 or cd T-cell receptor (TCR)
and phycoerythrin (PE)-conjugated anti-IL-17 antibody (n = 3–6 per
group). (c) cd T cells were purified as described in the Materials and
methods, and then the purified cd T cells (> 95% purity) were dou-
ble-stained with FITC-conjugated antibody against the cd TCR and
PE-conjugated anti-IL-17 antibody. (d) Purified cd+ T cells and
splenocytes lacking cd TCR (cd–) were stimulated for 48 hr with
anti-mouse CD3 antibody and IL-23, and then the supernatants were
collected and assayed for IL-17. The data are representative of those
for three independent assays. **P < 001 by Student’s t-test.
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Figure 4. Non-diabetic non-obese diabetic (NOD) mice have a
higher percentage of cd+ T cells than diabetic mice. (a, b) The per-
centage of cd T cells in (a) freshly isolated splenocytes and (b) inter-
leukin (IL)-23-expanded splenocytes from diabetic and non-diabetic
NOD mice of the same age was determined by flow cytometry. (c)
cd T cells isolated from 8-week-old non-diabetic and diabetic NOD
mice were stimulated for 48 hr with anti-mouse CD3 antibody and
IL-23, and then the supernatants were collected and assayed for
IL-17. Six mice were used in each group. The data are representative
of those for three independent assays.
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cd T cells protect NOD mice from diabetes by
up-regulating TGF-b
The mechanism by which cd T cells protect against diabe-
tes was then examined. As IL-17 can inhibit the produc-
tion of IFN-c,23–25 we first examined whether cd T cells
protected against diabetes by suppressing IFN-c produc-
tion. To investigate this, splenocytes from NOD-SCID
mice at 4 weeks after transfer of diabetic splenocytes or
co-transfer of cd T cells and diabetic splenocytes were
stimulated with anti-mouse CD3 antibody, and then,
48 hr later, the supernatants were collected and IL-17 and
IFN-c production measured by ELISA. As shown in
Fig. 6a, similar amounts of IFN-c were produced by
splenocytes from NOD-SCID mice that had received both
cd T cells and diabetic splenocytes or only diabetic
splenocytes, indicating that the protective effect of cd T
cells was not mediated by suppression of IFN-c produc-
tion. Co-transfer of cd T cells with splenocytes signifi-
cantly up-regulated IL-17 production (Fig. 6b). To
investigate the effect of cd T cells on IFN-c production in
another way, cd T cells were isolated and co-cultured
with diabetic T cells and anti-mouse CD3 antibody, and
then, 48 hr later, the supernatants were collected and
IFN-c and IL-17 production measured by ELISA. Again,
the cd T cells did not suppress the production of IFN-c
by diabetic splenocytes (data not shown), suggesting that
cd T cells protected NOD mice from diabetes via a mech-
anism not involving IFN-c.
As many reports have shown that cd T cells exert regula-
tory effects by producing TGF-b and/or IL-10,13,15,17 we
measured levels of TGF-b and IL-10 in NOD-SCID mice
that had undergone transfer of cd T cells or diabetic spleno-
cytes or co-transfer of cd T cells plus diabetic splenocytes.
TGF-b levels were significantly increased in the cd T cell-
protected NOD mice (Fig. 7a), but up-regulation of IL-10
was not seen (data not shown). When cells were also tested
for TGF-b expression after in vitro stimulation with anti-
CD3 antibody and IL-23, purified cd T cells were found to
produce higher levels of TGF-b than cd-negative T cells
(Fig. 7b), suggesting that TGF-b is the critical cytokine in
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Figure 5. Purified cd+ T cells protect non-obese diabetic (NOD) mice from diabetes. (a) cd T cells (15 · 106) were injected intravenously
(i.v.) into 7-week-old female NOD mice, untreated age- and sex-matched NOD mice being used as controls, and blood glucose was measured
biweekly. cd T cells protected NOD mice from diabetes (P = 00046 by the log-rank test). The data are representative of those for two inde-
pendent experiments. More than nine mice were used in each group. (b) Diabetic splenocytes (5 · 106) or purified cd T cells (5 · 106) alone
or diabetic splenocytes (5 · 106) plus 15 · 106 (30% cd T cells) or 75 · 105 (15% cd T cells) purified cd T cells were injected i.v. into
NOD–severe combined immunodeficiency (SCID) mice and blood glucose was measured weekly. Both 30% cd T cells (P < 0001) and 15%
cd T cells (P < 001) protected NOD-SCID recipients from diabetes (by the log-rank test). Ten mice were included in each experimental
group. The data are representative of those for three independent assays. (c) Photomicrographs of representative islets from NOD-SCID mice
6 weeks after transfer of diabetic splenocytes, diabetic splenocytes plus 30% cd T cells, or diabetic splenocytes plus 15% cd T cells. Animals
(n = 6 per group) were killed and a histological examination of the pancreatic islets (at least 60 islets per mouse) was performed on sections
stained with haematoxylin and eosin (H&E). Transfer of cd T cells alone does not cause insulitis (data not shown). The photomicrographs
shown are representative of those from more than five animals per group. (d) The insulitis score in the animals in (c) was determined as
described in the Materials and methods.
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The protective action of cd T cells is inhibited by
anti-TGF-b antibody
To determine whether this up-regulation of TGF-b in
NOD-SCID mice that had received cd T cells was func-
tionally relevant to the inhibition of diabetes, diabetic
splenocytes and purified cd T cells were co-transferred
into NOD-SCID mice, half of which were injected with
anti-TGF-b antibody every 4–5 days and half of which
were injected with control mouse IgG. All the mice
given control IgG were diabetes-free at 6 weeks after
transfer, while 50% of those given anti-TGF-b antibody
developed diabetes by 3 weeks after transfer (P < 0001
by the log-rank test) (Fig. 8), showing that TGF-b is
important in the protection against diabetes afforded by
cd T cells.
Discussion
The roles of Th17 cells in autoimmune disease remain
largely unclear. In the present study, we found that,
although diabetic T cells produced higher levels of IL-17
than non-diabetic cells, in vivo neutralization of IL-17 did
not prevent or delay the development of adoptively trans-
ferred diabetes. This suggests that the role of IL-17 in
autoimmune diabetes is not as critical as in multiple scle-
rosis or rheumatoid arthritis, in which the disease can be
delayed or prevented by neutralization or knock-out of
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Figure 6. Protection by cd T cells does not involve suppression of
interferon (IFN)-c production. (a, b) Splenocytes from non-obese
diabetic–severe combined immunodeficiency (NOD-SCID) mice
that had undergone transfer of cd T cells or diabetic splenocytes
or diabetic splenocytes plus 30% cd T cells were isolated and
stimulated for 48 hr with anti-CD3 antibody and interleukin (IL)-
23, and then the supernatants were assayed for IFN-c (a) or IL-17
(b) (n = 4 per group). The data are representative of those
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Cells from non-diabetic NOD mice
Figure 7. Involvement of transforming growth factor (TGF)-b in cd
T cell-mediated protection against diabetes. (a) Serum was collected
from non-obese diabetic–severe combined immunodeficiency (NOD-
SCID) mice that had undergone transfer of non-diabetic naı̈ve
splenocytes (from 6- to 8-week-old mice), cd T cells, diabetic spleno-
cytes or diabetic splenocytes plus 30% cd T cells and assayed for
TGF-b (n = 5 per group). (b) Purified cd+ and cd) T cells were
stimulated for 48 hr with anti-CD3 antibody and interleukin (IL)-23,
and then the supernatants were assayed for TGF-b. The data are rep-
resentative of those for three independent experiments. *P < 005;
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Figure 8. The protective effect of cd T cells against diabetes is inhib-
ited by anti-transforming growth factor (TGF)-b antibodies. Diabetic
splenocytes (5 · 106) plus 15 · 106 cd T cells were injected intrave-
nously (i.v.) into non-obese diabetic–severe combined immunodefi-
ciency (NOD-SCID) mice, and then one group was left untreated,
while two others were injected i.v. with either 05 mg of anti-TGF-b
antibody [1D11; mouse immunoglobulin G1 (IgG1)] or the same
amount of normal mouse IgG on the day of transfer, and then every
4–5 days. NOD-SCID mice that only received diabetic splenocytes
(5 · 106) were used as a positive control. Blood glucose was mea-
sured weekly. Anti-TGF-b antibodies significantly inhibited the pro-
tective effect of cd T cells in vivo (P < 0001 by the log-rank test).
The data are representative of those for three independent assays. In
each experiment, 10 mice were used in each group.
 2009 Blackwell Publishing Ltd, Immunology, 129, 197–206 203
Regulatory IL-17-producing cd T cells in NOD mice
play a less important role in the pathogenesis of diabetes
than Th1 cells,9,10 the precise roles of IL-17 and IL-17-
producing cells in natural conditions in autoimmune dia-
betes remain to be investigated.
It is well known that IL-23 is the most important cyto-
kine for expanding Th17 cells and promoting IL-17 pro-
duction, but is less effective in promoting IFN-c
production.23,25 Thus, IL-23 significantly enhanced IL-17
production in diabetic T cells, while IFN-c secretion was
not affected compared with the non-IL-23-treated cells
(Fig. 2a,b). However, transfer of diabetic splenocytes
expanded by IL-23 did not result in an increased inci-
dence of diabetes in recipients (Fig. 2c), again indicating
that the presence of IL-17 did not increase the incidence
of diabetes development in NOD mice.
IFN-c was found to be involved in the pathogenesis of
autoimmune diabetes in NOD mice in early reports.2
When the kinetics of IL-17 and IFN-c production in
NOD mice were examined, we found that IFN-c produc-
tion peaked at the age of onset of insulitis in NOD mice,
while IL-17 production was virtually unchanged with age.
This result contrasts with the pattern seen in EAE, in
which the IL-17 peak appears earlier than the IFN-c
peak.26 These data again suggest that IFN-c and not IL-17
is involved in the progression of diabetes.
Many types of cell, including CD4+, CD8+ and cd T
cells, are known to produce IL-17.11 What are the IL-17-
producing cells in NOD mice and do they affect the pro-
cess of diabetes? IL-17-producing cells in NOD mice were
identified and their function investigated. Our data
showed that (i) cd T cells were the major source of IL-17
in NOD mice, (ii) cd T cells were dominated by IL-17-
expressing cells, and (iii) purified cd T cells produced 10
times more IL-17 than splenocytes lacking cd TCR in
response to stimulation by anti-mouse CD3 antibody and
IL-23. These data suggested that cd T cells might domi-
nate the IL-17 response in some circumstances, which is
in accordance with the findings of other studies.11,27.
As the cd T cells were dominated by IL-17-producing
cells, the function of cd T cells in diabetes is of interest.
Different roles of cd T cells have been reported in inflam-
matory and autoimmune diseases. Some reports showed
that cd T cells in type 1 diabetes and other autoimmune
diseases are protective or regulatory,13–19 while others
showed that they could either act as antigen-presenting
cells to initiate immunity or provide a first line of defence
through the recognition of self-antigens expressed on
damaged or stressed cells.28,29 These results show that cd
T cells perform different functions according to their
tissue distribution, antigen-receptor structure, and local
microenvironment.
The roles of IL-17-producing cd T cells in autoimmune
diabetes were subsequently examined. When purified cd T
cells were co-transferred with diabetic T cells at different
ratios, cd T cells showed regulatory effects in NOD mice.
Consistent with the above results, the percentage of cd T
cells was found to be lower in the diabetic than in the
non-diabetic NOD mice.
We then examined the mechanism by which IL-17-
producing cd T cells prevented diabetes in NOD-SCID
mice. Because some reports have shown that expression
of IL-17 and IFN-c is mutually suppressive,23,24 we first
tested whether the higher level of IL-17 production by cd
T cells suppressed IFN-c production. Our data showed
that IFN-c production was not suppressed in the cd T
cell-protected mice and IL-17 production was positively
correlated with the number of transferred cd T cells
(Fig. 6). Why IFN-c production was not suppressed might
be explained as follows: (i) cd T cells might function as
antigen-presenting cells and promote the production of
IFN-c by splenocytes;28 and (ii) as shown by Peng,18 regu-
latory cd T cells might secrete IFN-c. Our data suggested
that cd T cells protect NOD mice from diabetes through
a mechanism not involving IFN-c.
As cd T cells have been reported to have regulatory
effects by producing TGF-b and/or IL-10,13,15,17 we exam-
ined whether cd T cells protected NOD mice via a mech-
anism involving TGF-b and/or IL-10. To investigate this,
we first measured the production of TGF-b and IL-10 by
purified cd T cells in response to anti-mouse CD3 anti-
body and IL-23. Purified cd+ T cells secreted significantly
more TGF-b than cd) T cells. However, no significant
difference in IL-10 production was seen between the two
groups (data not shown). Our data indicate that cd T
cells might exert regulatory effects by producing TGF-b.
To further determine whether transferred cd T cells pro-
tected NOD mice from diabetes by up-regulating TGF-b
production in vivo, TGF-b levels were measured in serum
collected from recipient NOD-SCID mice that had under-
gone transfer of cd T cells, diabetic splenocytes, or non-
diabetic splenocytes alone or cd T cells plus diabetic
splenocytes. As expected, cd T cell-protected NOD mice
produced significantly higher levels of TGF-b than control
mice (Fig. 7). To confirm this, an in vivo TGF-b neutral-
ization study was performed and, as shown in Fig. 8,
administration of anti-TGF-b antibody blocked the cd T
cell-mediated protection against diabetes (P < 0001),
indicating that TGF-b is involved in the mechanism
underlying the cd T cell-mediated protection.
Recently, there have been reports that the function of
cd T cells is subset-dependent.20,30 However, on the ques-
tion of whether one cd T cell subset produces IL-17 while
another produces TGF-b, the results are not consistent.
For example, Roark30 showed that the vc4 subset is the
major source of IL-17 and that the vc1 subset produces
virtually no IL-17. However, Romani et al.31 found that
the vc1 subset mainly produces IL-17 and the vc4 subset
mainly produces IL-10. Again, this suggests that cd T cells
perform different functions depending on their tissue dis-
tribution and local microenvironment.
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Here we showed that IL-17-producing cd T cells were
suppressive. However, the roles of IL-17-producing CD4+
Th17 cells in NOD mice remain to be determined. Recent
findings obtained by McGeachy,32 who showed that CD4+
Th17 cells that co-produce IL-10 have regulatory proper-
ties, suggest that the presence of IL-17 may not increase
the chance of disease development, but the ability of
IL-17-producing cells to secrete other cytokines may be
a major determinant in their function as pathogenic or
tolerogenic cells.
Overall, our data suggest that IL-17 is not the critical
pro-inflammatory cytokine in the pathogenesis of auto-
immune diabetes in NOD mice. cd T cells, the major
source of IL-17 in NOD mice, protect NOD mice from
diabetes in a TGF-b-dependent way.
Acknowledgements
This work was supported by the National Natural
Sciences Foundation of China (Grant No. 30801029) and
a National ‘973’ Fund Grant of China (No. 2007CB
512406).
Disclosures
The authors have no financial conflict of interest.
References
1 Anderson MS, Bluestone JA. The NOD mouse: a model of
immune dysregulation. Annu Rev Immunol 2005; 23:447–85.
2 Savinov AY, Wong FS, Chervonsky AV. IFN-g affects the hom-
ing of diabetogenic T cells. J Immunol 2001; 167:6637–43.
3 Han G, Li Y, Wang J et al. Active tolerance induction and pre-
vention of autoimmune diabetes by immunogene therapy using
recombinant adenoassociated virus expressing glutamic acid
decarboxylase 65 peptide GAD (500-585). J Immunol 2005;
174:4516–24.
4 Cooke A, Phillips JM, Parish NM. Tolerogenic strategies to halt
or prevent type 1 diabetes. Nat Immunol 2001; 2:810.
5 Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells
regulates tissue inflammation by producing interleukin 17. Nat
Immunol 2005; 6:1133–41.
6 Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune
induction of collagen-induced arthritis in IL-17-deficient mice.
J Immunol 2003; 171:6173–7.
7 Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than
interleukin-12 is the critical cytokine for autoimmune inflamma-
tion of the brain. Nature 2003; 421:744–8.
8 Hashimoto T, Akiyama K, Kobayashi N, Mori A. Comparison of
IL-17 production by helper T cells among atopic and nonatopic
asthmatics and control subjects. Int Arch Allergy Immunol 2005;
137:51–4.
9 Bending D, De La Pea H, Veldhoen M, Phillips JM, Uyttenhove
C, Stockinger B, Cooke A. Highly purified Th17 cells from
BDC25NOD mice convert into Th1-like cells in NOD/SCID
recipient mice. J Clin Invest 2009, doi: 10.1172/JCI37865.
10 Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C.
Th17 cells promote pancreatic inflammation but only induce
diabetes efficiently in lymphopenic hosts after conversion into
Th1 cells. Eur J Immunol 2009; 39:216–24.
11 Lockhart E, Green AM, Flynn JL. IL-17 production is dominated
by cdT cells rather than CD4 T cells during Mycobacterium
tuberculosis infection. J Immunol 2006; 177:4662–9.
12 Shibata K, Yamada H, Hara H, Kishihara K, Yoshikai Y. Resi-
dent Vc1cdT cells control early infiltration of Neutrophils after
Escherichia coli infection via IL-17 production. J Immunol 2007;
178:4466–72.
13 Bhagat G, Naiyer AJ, Shah JG, Harper J, Jabri B, Wang TC,
Green PH, Manavalan JS. Small intestinal CD8+TCRcd+
NKG2A+ intraepithelial lymphocytes have attributes of regula-
tory cells in patients with celiac disease. J Clin Invest 2008;
118:281–93.
14 Harrison LC, DempseyCollier M, Kramer DR, Takahashi K.
Aerosol insulin induces regulatory CD8 gd T cells that pre-
vent murine insulin-dependent diabetes. J Exp Med 1996;
184:2167–74.
15 Seo N, Tokura Y, Takigawa M, Egawa K. Depletion of IL-10-
and TGF-b-producing regulatory gd T cells by administering a
daunomycin -conjugated specific monoclonal antibody in early
tumor lesions augments the activity of CTLs and NK cells.
J Immunol 1999; 163:242–9.
16 Locke NR, Stankovic S, Funda DP, Harrison LC. TCR gd intra-
epithelial lymphocytes are required for self-tolerance. J Immunol
2006; 176:6553–9.
17 Nagaeva O, Jonsson L, Mincheva-Nilsson L. Dominant IL-10
and TGF-b mRNA expression in gdT cells of human early preg-
nancy decidua suggests immunoregulatory potential. Am J
Reprod Immunol 2002; 48:9–17.
18 Peng G, Wang H, Peng W, Kiniwa Y, Seo KH, Wang R. Tumor-
infiltrating gammadelta T cells suppress T and dendritic cell
function via mechanisms controlled by a unique Toll-like recep-
tor signaling pathway. Immunity 2007; 27:334–48.
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